The following is the Beutner Clinical Trial Report that inspired my Dermatologist to experiment with Aldara in my treatment.






These are the type of incomplete and over exaggerated clinical trial documents that your own dermatologists read, perhaps during a short break between patients, that has overwhelming influence on their decision to use, or experiment with, Aldara in your treatments.  Many dermatologists fail to study or care to invest their valuable time understanding the drug mechanism involved with Aldara but would rather choose to read these types of 3M self-induced positive promotional articles where 3M "summarizes" what "they" want your  dermatologist to know about Aldara.  If these articles were balanced with the truth, few doctors would even remotely consider prescribing Aldara for any purpose in their practices. 

3M virtually designs the protocols on their clinical trials for specific positive outcomes that promote the sales of Aldara with a total disregard to your safety or well-being.  Once they have the data in place, it becomes a most  effective and valuable marketing tool.  In the past, 3M & now Graceway drug reps regularly visit the offices of your dermatologist where they conduct a  " right in their face " high pressure, promotional style, sales pitch that leaves your physician with the concept that Aldara is a benign and safe drug that "everyone" else is prescribing with overwhelmingly safe and efficacious results.  

 This entire, well orchestrated,  sales pitch is designed to leave your  physician with the impression or illusion that:  

 " If  I  don't  get  on  the  bandwagon  I  will  be  left  behind"


J Am Acad Dermatol. 1999 Dec;41(6):1002-7.

Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream.

Beutner KR, Geisse JK, Helman D, Fox TL, Ginkel A, Owens ML.

Department of Dermatology, University of California, San Francisco, the Department of Medicine, Sutter Solano Medical Center, Vallejo, Solano Dermatology Associates, Vallejo, CA, USA.



BACKGROUND: Basal cell carcinoma (BCC) responds to interferon therapy. Imiquimod is a cytokine and interferon inducer.

OBJECTIVE: This randomized, double-blind pilot trial evaluated the safety and efficacy of imiquimod 5% cream versus vehicle in the treatment of BCC.

METHODS: In this population of 35 patients with BCC, 24 received imiquimod 5% cream and 11 received vehicle cream in 1 of 5 dosing regimens for up to 16 weeks. Six weeks after treatment, an excisional biopsy of the target site was performed.

RESULTS: BCC cleared (on the basis of histologic examination) in all 15 patients (100%) dosed twice daily, once daily, and 3 times weekly; in 3 of 5 (60%) patients dosed twice weekly; 2 of 4 (50%) dosed once weekly; and in 1 of 11 (9%) treated with vehicle. Adverse events were predominantly local reactions at the target tumor site, with the incidence and severity of local skin reactions declining in groups dosed less frequently.

CONCLUSION: Imiquimod 5% cream shows clinical efficacy in the treatment of BCC.